Spots Global Cancer Trial Database for MElanoma Research Lymph Node Prediction Implementation National_001
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MElanoma Research Lymph Node Prediction Implementation National_001
Official Title: A Prospective Registry Study of a Primary Melanoma Gene-signature to Predict Sentinel Node (SN) Status and Determine Its Prognostic Value for More Accurate Staging of SN-negative Melanoma Patients.
Study ID: NCT04759781
Conditions
Interventions
Study Description
Brief Summary: MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Emory University School of Medicine, Atlanta, Georgia, United States
University of Kentucky, Lexington, Kentucky, United States
University of Louisville, Louisville, Kentucky, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Duke University, Durham, North Carolina, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact Details
Name: Vernon K. Sondak, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Name: Tina J. Hieken, MD
Affiliation: Mayo Clinic
Role: PRINCIPAL_INVESTIGATOR
Name: Michael E. Egger, MD, MPH
Affiliation: University of Louisville
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
